VERU Earnings — Veru Inc. Post-ER Performance | BigEarnings
VERU — Veru Inc.
XNAS · Healthcare · Biotechnology
Price$2.32
Market Cap$37.4M
P/E—
52W Range$2.05 – $7.40
Next Earnings2026-08-11
About Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
